A股午評：滬指升0.17% 超3400股上升 鈦白粉、減肥藥概念領升
A股主要指數低開高走，截至午間收盤，滬指升0.17%報3049.9點，深證成指升0.41%，創業板指升0.33%。超3400股上升，兩市半日成交4993億元，北向資金淨賣出約2.8億元。
盤面上，鈦白粉概念盤初拉昇，安納達、金浦鈦業、魯北化工升停，魯北化工一季度淨利潤5054.14萬元，同比增長3131.39%；減肥藥概念股震盪走高，常山藥業20cm升停，常山藥業公吿稱，子公司開發的艾本那肽注射液(GLP-1受體激動劑)首個新藥上市申請已獲國家藥監局受理；低空經濟概念股反覆活躍，川大智勝2連板，多地出台政策支持，小鵬匯天飛行汽車將亮相北京車展；PEEK材料、磷化工、CRO等板塊升幅居前。小家電板塊走低，比依股份跌停，一季度歸母淨利潤1015萬元，同比下降78.12%；國防軍工板塊回調，北摩高科跌近9%；國產航母、中船系、貴金屬等板塊跌幅居前。
鈦白粉概念盤初拉昇 安納達等多股升停
安納達、金浦鈦業、魯北化工升停，惠雲鈦業升超18%，天原股份、中核鈦白、釩鈦股份升幅靠前。消息面上，惠雲鈦業去年實現淨利潤同比增近190%；此前行業龍頭龍佰集團一季度淨利潤同比增64%。
減肥藥概念股震盪走高 常山藥業升停
常山藥業20cm升停，博瑞醫藥、博濟醫藥、百花醫藥、翰宇藥業、皓元醫藥等跟升。消息面上，常山藥業昨日公吿稱，由控股子公司常山凱捷健生物藥物研發(河北)有限公司開發的艾本那肽注射液(GLP-1受體激動劑)首個新藥上市申請(NDA)已獲國家藥品監督管理局(NMPA)受理，申報的適應症為用於治療2型糖尿病。
低空經濟概念股反覆活躍 川大智勝2連板
川大智勝2連板，中衡設計7連板，建新股份升近11%，萬豐奧威、雙一科技、深城交、萊斯信息等跟升。消息面上，昨日，瀋陽制定發佈《瀋陽市低空經濟高質量發展行動計劃(2024-2026年)》，其中提出打造10個以上低空經濟應用示範場景，培育低空經濟相關企業突破100家，產業規模達到30億元。此外，小鵬匯天宣佈，其陸空一體式飛行汽車將於4月25日至5月4日亮相北京車展。
國防軍工板塊回調 北摩高科跌超9%
北摩高科跌超9%，觀想科技、航天長峯、光威復材跌超7%，四創電子、北斗星通、天微電子、振華風光等跟跌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
